Navigation Links
Research suggests popular diabetes drugs can cause abnormal pancreatic growth in humans
Date:3/27/2013

Individuals who had taken a type of drug commonly used to treat Type 2 diabetes showed abnormalities in the pancreas, including cell proliferation, that may be associated with an increased risk of neuroendocrine tumors, according to a new study by researchers from UCLA and the University of Florida. Their findings were published online March 22 in the journal Diabetes.

The researchers, from the Larry L. Hillblom Islet Research Center at UCLA and the Diabetes Center at the University of Florida, found that cell mass was increased approximately 40 percent in the pancreases of deceased organ donors who had Type 2 diabetes and who had been treated with incretin therapy. This widely used type of treatment takes advantage of the action of a gut hormone known as glucagon-like peptide 1 (GLP-1) to lower blood sugar in the body.

Although there have been conflicting reports on the effects of the incretin class of drugs on the pancreas in animal studies, this is the first study to note such changes in the human pancreas. The research was made possible by a unique research consortium called nPOD (Network for Pancreatic Organ Donors with Diabetes), led by Dr. Mark Atkinson, a professor of pathology and pediatrics at the University of Florida. The network, which is funded by the Juvenile Diabetes Research Foundation, obtains pancreases from deceased organ donors, with permission of their next of kin, to better understand diabetes by investigating tissues of those with the disease.

"There is an increasing appreciation that animal studies do not always predict findings in humans," said Dr. Peter Butler, director of UCLA's Hillblom Islet Research Center and chief of the endocrinology, diabetes and hypertension unit. "The nPOD program is therefore a very precious resource." The researchers examined the pancreases of 20 deceased organ donors with Type 2 diabetes. Eight had been treated for at least a year with incretin therapy, while the other 12 had received therapies that didn't include incretin-based drugs. The researchers also evaluated 14 pancreases from a control group of non-diabetic individuals of similar age.

The pancreases of the individuals who had been on incretin therapy were larger than those of patients on other types of diabetes therapies, and this larger size was associated with increased cellular proliferation. Incretin-treated individuals showed an increase in pancreas dysplasia, an abnormal form of cell proliferation that is a risk factor for pancreatic cancer, as well as an expansion of alpha cells, endocrine cells that make the hormone glucagon.

This latter finding is likely a consequence of GLP-1based therapies' suppression of the release of glucagon by alpha cells, since decreasing the availability or action of the hormone glucagon has been shown in a variety of prior studies to induce a proliferation of pancreatic alpha cells. This alpha-cell expansion has been associated with the development of pancreatic neuroendocrine tumors. Three of the eight incretin-treated individuals had microadenomas and one has a neuroendocrine tumor composed of alpha cells.

Of the eight donors who were on incretin therapy, seven had been taking sitagliptin, sold in pill form as Januvia and marketed by Merck, and one had been on exenatide, sold as Byetta by Bristol-Myers Squibb. These and similar drugs are currently under investigation by the U.S. Food and Drug Administration for their possible links to pancreatitis and pancreatic cancer.

"These findings lend additional weight to concerns regarding the effects of long term GLP-1related therapy, with respect to both unintended proliferative actions on the exocrine pancreas and now also a possible increased risk of neuroendocrine tumors," the researchers write. "In addition to the surveillance previously recommended for the potential association of GLP-1 based therapy and pancreatic cancer risk, the current data imply that surveillance for a possible increased risk of pancreatic neuroendocrine tumors is warranted."

Such surveillance approaches might include MRI imaging of the pancreas and screening for neuroendocrine tumors, Butler said.

"The present studies are only from a small number of individuals, and while the findings do raise concerns, it will be important that other approaches are now used in a larger group of living individuals to further investigate these findings," he said.

A recent study led by Dr. Sonal Singh of Johns Hopkins University School of Medicine and Public Health and published in JAMA Internal Medicine suggested a doubling in the risk of hospitalization for acute pancreatitis with the GLP-1based therapies and also recommended further research.

"Since most risk factors for acute pancreatitis are also linked to an increased risk of pancreatic cancer, these findings of changes in the human pancreas are very concerning," said Singh, an assistant professor of medicine and international health. "Now that GLP-1based therapies have been shown to increase the risk of pancreatic inflammation and abnormal cell proliferation, further studies are needed to urgently clarify whether these linkages lead to pancreatic cancer with long-term use."


'/>"/>
Contact: Enrique Rivero
erivero@mednet.ucla.edu
310-794-2273
University of California - Los Angeles Health Sciences
Source:Eurekalert

Related medicine news :

1. Frozen Food Production in the US Industry Market Research Report from IBISWorld has Been Updated
2. Moffitt researchers analyze HPV vaccination disparities among girls from low-income families
3. Penn research: Quitting marshmallow test can be a rational decision
4. Notre Dame researchers scoring a win-win with novel set of concussion diagnostic tools
5. GW professor researching ways to improve human tissue dissection, reduce blood transfusions
6. Researchers form new nerve cells &#8211 directly in the brain
7. Wake Forest Baptist research provides clues to alcohol addiction vulnerability
8. Research and Markets Announces the Release of Global Biobank (Biospecimen/Biorepository/Biopreservation) Market For Equipment & Media – Trends & Forecast to 2017
9. Moffitt Cancer Center researchers design small molecule to disrupt cancer-causing protein
10. UW researchers discover the brain origins of variation in pathological anxiety
11. Researchers decode biology of blood and iron disorders mapping out novel future therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... The Professional Squash ... has enlisted New York City-based sports and entertainment marketing firm Leverage Agency as ... opportunities for the Professional Squash Association (PSA), which includes first-time ever title sponsorship, ...
(Date:3/29/2017)... ... ... Sublime Naturals and its founder, Kathy Heshelow, are big fans of Turmeric. ... for thousands of years. , "The West has caught on, and has discovered Turmeric, ... Use it For Your Wellness. Overcome Inflammation, Enemy of the Body. " The ...
(Date:3/29/2017)... ... March 29, 2017 , ... Based on research from ... employers face in trying to balance both short-term and long-term benefits demands. ... to the growing complexity, companies are finding that the short-term strategies used to ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... documenting and diagramming network and data center assets and audio-video devices has recently ... request new equipment shapes for free and download shapes and stencils from ...
(Date:3/29/2017)... ... March 29, 2017 , ... Immunotherapy has emerged as one of ... and is touted to be the next revolution in our fight against this complex ... the form of immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 29, 2017 Wound care devices and products ... the wound. The industry mainly consists of establishments engaged ... treatment of wounds caused by mechanical, chemical, thermal, and ... such as diabetes, skin related diseases, immunological diseases, and ... was the largest region in the wound care ...
(Date:3/29/2017)... Mar. 29, 2017 Research and Markets has ... report to their offering. ... The global gas chromatograph market to grow at ... The report, Global Gas Chromatograph Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
(Date:3/29/2017)... DIEGO , March 29, 2017 Avelas Biosciences, Inc., ... from diagnosis through treatment, today announced that Carmine N. Stengone ... the company at the Needham & Company 16 th Annual ... (8:20 a.m. PDT) at the Westin Grand Central Hotel in ... ...
Breaking Medicine Technology: